47 related articles for article (PubMed ID: 38211967)
21. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
22. Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience.
Aggerholm-Pedersen N; Rossen P; Rose H; Safwat A
Transl Oncol; 2020 Feb; 13(2):295-299. PubMed ID: 31875575
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients.
Weitao Y; Fangxing W; Qiqing C; Jiaqiang W
Anticancer Drugs; 2019 Aug; 30(7):e0778. PubMed ID: 31305297
[TBL] [Abstract][Full Text] [Related]
24. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
[TBL] [Abstract][Full Text] [Related]
25. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.
Qin S; Li A; Yi M; Yu S; Zhang M; Wu K
J Hematol Oncol; 2019 Mar; 12(1):27. PubMed ID: 30866992
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety.
Liao Z; Li F; Zhang C; Zhu L; Shi Y; Zhao G; Bai X; Hassan S; Liu X; Li T; Xing P; Zhao J; Zhang J; Xing R; Teng S; Yang Y; Chen K; Yang J
Exp Mol Med; 2019 Feb; 51(3):1-11. PubMed ID: 30816108
[TBL] [Abstract][Full Text] [Related]
27. More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments.
Katz D; Palmerini E; Pollack SM
Am Soc Clin Oncol Educ Book; 2018 May; 38():925-938. PubMed ID: 30231352
[TBL] [Abstract][Full Text] [Related]
28. Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas.
Zhang Q; Xiang W; Yi DY; Xue BZ; Wen WW; Abdelmaksoud A; Xiong NX; Jiang XB; Zhao HY; Fu P
Stem Cell Res Ther; 2018 Aug; 9(1):228. PubMed ID: 30143053
[TBL] [Abstract][Full Text] [Related]
29. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.
;
Cell; 2017 Nov; 171(4):950-965.e28. PubMed ID: 29100075
[TBL] [Abstract][Full Text] [Related]
31. Managing sarcoma: where have we come from and where are we going?
Bleloch JS; Ballim RD; Kimani S; Parkes J; Panieri E; Willmer T; Prince S
Ther Adv Med Oncol; 2017 Oct; 9(10):637-659. PubMed ID: 28974986
[TBL] [Abstract][Full Text] [Related]
32. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.
Siemann DW; Chaplin DJ; Horsman MR
Cancer Invest; 2017 Sep; 35(8):519-534. PubMed ID: 28872367
[TBL] [Abstract][Full Text] [Related]
33. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma.
Liu K; Ren T; Huang Y; Sun K; Bao X; Wang S; Zheng B; Guo W
Cell Death Dis; 2017 Aug; 8(8):e3015. PubMed ID: 28837148
[TBL] [Abstract][Full Text] [Related]
34. Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
Karasic TB; Rosen MA; O'Dwyer PJ
Cancer Chemother Pharmacol; 2017 Oct; 80(4):661-671. PubMed ID: 28721456
[TBL] [Abstract][Full Text] [Related]
35. Advanced alveolar soft part sarcoma responds to apatinib.
Zhou Y; Tang F; Wang Y; Min L; Luo Y; Zhang W; Shi R; Duan H; Tu C
Oncotarget; 2017 Jul; 8(30):50314-50322. PubMed ID: 28679123
[TBL] [Abstract][Full Text] [Related]
36. Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report.
Peng Y; Cui H; Liu Z; Liu D; Liu F; Song Y; Duan H; Qiu Y; Li Q
Onco Targets Ther; 2017; 10():2289-2295. PubMed ID: 28490886
[TBL] [Abstract][Full Text] [Related]
37. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
Dickson MA; Schwartz GK; Keohan ML; D'Angelo SP; Gounder MM; Chi P; Antonescu CR; Landa J; Qin LX; Crago AM; Singer S; Koff A; Tap WD
JAMA Oncol; 2016 Jul; 2(7):937-40. PubMed ID: 27124835
[TBL] [Abstract][Full Text] [Related]
38. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.
Sun H; Zhu MS; Wu WR; Shi XD; Xu LB
World J Hepatol; 2014 Dec; 6(12):830-5. PubMed ID: 25544869
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
Dickson MA; Tap WD; Keohan ML; D'Angelo SP; Gounder MM; Antonescu CR; Landa J; Qin LX; Rathbone DD; Condy MM; Ustoyev Y; Crago AM; Singer S; Schwartz GK
J Clin Oncol; 2013 Jun; 31(16):2024-8. PubMed ID: 23569312
[TBL] [Abstract][Full Text] [Related]
40. Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans.
Ding J; Chen X; Gao Z; Dai X; Li L; Xie C; Jiang H; Zhang L; Zhong D
Drug Metab Dispos; 2013 Jun; 41(6):1195-210. PubMed ID: 23509226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
